Appointment of Nicolas Serandour

RNS Number : 0505Q

Advanced Oncotherapy PLC

27 August 2014

 



27 August 2014

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Advanced Oncotherapy Appoints Nicolas Serandour as new Global Head of Finance

Advanced Oncotherapy (AIM: AVO), the developer of the next generation of proton-particle therapy for treating cancer, announces that it will appoint Nicolas Serandour as Global Head of Finance and as an Executive Director, effective September 1^st. Graham Pughe, who will continue with the Company as Vice President of Finance and Chief Accounting Officer, will report to Nicolas.
 
Nicolas has over 15 years of experience in the investment banking industry, having worked at JP Morgan, Lehman Brothers and Lazard, where he was most recently responsible for coordinating the European Healthcare sector coverage.  He has extensive experience providing strategic and financial advice to senior executives and boards of directors at leading healthcare companies internationally. His transaction experience covers a wide range of private and public strategic transactions, including acquisitions, divestitures, complex alliances and funding of growth companies.
 
Sanjeev Pandya, CEO of Advanced Oncotherapy commented: "We are delighted to welcome Nicolas on board as Global Head of Finance.  We look forward to working together with him and profiting from his enormous know-how and industry experience.  Our current priority is execution and creating value. Nicolas knows the healthcare industry well. He brings with him a great combination of finance, capital allocation, value-based planning and strategy skills - critically needed skills as we execute our strategy and deliver long-term value to our shareholders and focus on excellence in execution."
 
Commenting on his appointment Nicolas Serandour said: "I am looking forward to working with Sanjeev and the team to deliver Advanced Oncotherapy's exciting growth strategy. It is a tremendous opportunity to join a company that is at the forefront of the development of proton-therapy systems. I look forward to working with the team to build on its successes and deliver on the opportunities in this next stage of its evolution."

For further information contact:

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya (CEO)	Tel: [phone]
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson	Tel: [phone]
Walbrook PR (Financial PR & IR)	[e-mail]
Anna Dunphy / Mike Wort	Tel: [phone]

About Advanced Oncotherapy Plc

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

For more information, please visit http://www.avoplc.com

Appendix - AIM Rule 17 and Schedule Two (g) of the AIM Rules for Companies

Nicolas Serandour - current directorships

Good Listing Limited

Totally Listed Limited

Save for the information above, there are no further disclosures to be made in accordance with Rule 17, Schedule Two (g) of the AIM Rules for Companies in respect of the appointment of Nicolas Serandour, who is 39 years of age.

 

END

 

 

BOAQKADNPBKDPFB